Inhibrx Biosciences Inc.
INBX | NASDAQ
$112.93
+$0.89 (+0.79%)
Sep 22, 2026, 2:09 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -8.74 | 0.13 | -7.42 | -6.81 | -20.31 | -11.03 |
PEG Ratio | 0.08 | 0 | -0.18 | -0.10 | 0.72 | -0.10 |
PS Ratio | 941.13 | 1.11K | 994.97 | 450.85 | 229.55 | 65.03 |
PB Ratio | 153.07 | 1.67 | 41.17 | 17.02 | 31.69 | 11.04 |
P/FCF Ratio | -9.42 | -1.13 | -9.05 | -8.52 | -20.45 | -16.88 |
P/OCF Ratio | -9.43 | -1.15 | -9.26 | -8.57 | -20.67 | -17.36 |
OCF/S Ratio | -9.98K | -97.2K | -10.74K | -5.26K | -1.11K | -374.52 |
Debt / Equity Ratio | 13.39 | 0.06 | 4.83 | 3.57 | 1.38 | 0.50 |
Quick Ratio | 3.93 | 3.94 | 5.25 | 10.17 | 6.23 | 8.33 |
Current Ratio | 3.93 | 3.94 | 5.25 | 10.17 | 6.20 | 4.21 |
Asset Turnover | 0.01 | 0 | 0.01 | 0.01 | 0.05 | 0.09 |
Interest Coverage | -11.07 | -24.57 | -6.89 | -8.02 | -14.68 | -6.24 |
Return on Equity | -1.75K% | 1.26K% | -554.81% | -250.14% | -156.10% | -100.22% |
Return on Assets | -95.61% | 933.56% | -78.39% | -49.93% | -54.35% | -52.62% |
Return on Invested Capital | -117.41% | -234.02% | -86.43% | -48.69% | -59.05% | -59.24% |
Dividend Yield | n/a | 5.52% | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | 0.73% | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | -91% | -1.04K% | 33.83% | -4.93K% | 100% | -473.82% |
Net Profit Margin | -10.77K% | 843.79K% | -13.41K% | -6.63K% | -1.13K% | -590.54% |
Pretax Profit Margin | -10.77K% | 843.79K% | -13.32K% | -6.63K% | -1.13K% | -590.52% |
Operating Profit Margin | -10.39K% | -165.72K% | -12.18K% | -5.89K% | -1.06K% | -526.57% |
FCF Margin | -9.99K% | -98.5K% | -10.99K% | -5.29K% | -1.12K% | -385.17% |
EBITDA Margin | -9.64K% | 851.68K% | -11.48K% | -5.74K% | -1.06K% | -498.12% |
Add to Watchlist
Select watchlists to add or remove INBX